HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Toxicology Forum

This article was originally published in The Rose Sheet

Executive Summary

Nonprofit organization "devoted to conducting open dialogues among various segments of society concerned with problems in toxicology" will hold its 35 annual summer meeting July 12-16 at the Given Institute in Aspen, Colorado. Research Institute for Fragrance Materials' Anne Marie Api, VP of human health sciences, will chair half-day session entitled "Quantitative Risk Assessment for Dermal Sensitization: What's An Acceptable Exposure?" Panel discussion will involve Procter & Gamble's Carsten Goebel, who will speak on the scientific principles of dermal sensitization risk assessment, as well as dermatologist Donald Belsito of the University of Missouri, who will provide a medical perspective, and the Consumer Products Safety Commission's Joanna Matheson, who will offer a regulatory view. Linda Katz from FDA and Alan Andersen, scientific director of the Cosmetic Ingredient Review, also will participate. Other sessions planned for the Toxicology Forum's July meeting include "Manufactured Nanoscale Materials: Carbon Nanotube Toxicology," "NAS Report on Phthalates and Cumulative Risk Assessment: The Task Ahead," and "Can Carcinogenicity Be Predicted by 6- or 12-Month in vivo Toxicology Data? Results from Analysis of a New Pharmaceutical Database.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel